Zahid Kocak M. Comment on ‘Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab’. AO [Internet]. 2021 Apr. 3 [cited 2026 May 31];60(4):564-5. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/21487